Adults and paediatric patients (≥ 12 years of age weighing at least 40 kg)
Mild-to-moderate COVID-19
Positive results of direct SARS-CoV-2 viral testing
High risk for progression to severe COVID-19
You may not be if
Patients who are hospitalised due to COVID-19 before sotrovimab administration
Patients who require oxygen therapy due to COVID-19 before sotrovimab administration oPatients who received pharmacological treatment including monoclonal antibodies to any components of SARS-CoV-2 virus within 6 months prior to enrolment into the study in retrospective and prospective arms.
Clareo Health | Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain
